Cargando…
Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment—Preliminary Data
SIMPLE SUMMARY: Galectin-3 (gal-3) regulates many different biological processes and diseases, which are common accompanying diseases of psoriasis. Psoriasis is one of the most common skin diseases. There is little information about potential diagnostic role of gal-3 in psoriasis. Serum gal-3 concen...
Autores principales: | Baran, Anna, Kiluk, Paulina, Nowowiejska, Julia, Kaminski, Tomasz W., Maciaszek, Magdalena, Flisiak, Iwona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773359/ https://www.ncbi.nlm.nih.gov/pubmed/35053087 http://dx.doi.org/10.3390/biology11010088 |
Ejemplares similares
-
Decreased levels of vaspin and its potential association with cardiometabolic risk in patients with psoriasis: preliminary results
por: Kiluk, Paulina, et al.
Publicado: (2021) -
Potential Predictive Value of Serum Pentraxin 3 and Paraoxonase 1 for Cardiometabolic Disorders Development in Patients with Psoriasis—Preliminary Data
por: Baran, Anna, et al.
Publicado: (2022) -
Circulating ANGPTL8 as a Potential Protector of Metabolic Complications in Patients with Psoriasis
por: Baran, Anna, et al.
Publicado: (2023) -
Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis
por: Baran, Anna, et al.
Publicado: (2020) -
Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis
por: Baran, Anna, et al.
Publicado: (2019)